Home/Filings/4/0000950170-25-023580
4//SEC Filing

Henn Matthew R. 4

Accession 0000950170-25-023580

CIK 0001609809other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 8:10 PM ET

Size

13.0 KB

Accession

0000950170-25-023580

Insider Transaction Report

Form 4
Period: 2025-02-15
Henn Matthew R.
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-15+2,81380,583 total
  • Exercise/Conversion

    Common Stock

    2025-02-15+7,81388,396 total
  • Sale

    Common Stock

    2025-02-18$0.81/sh3,953$3,20484,443 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-152,81322,500 total
    Common Stock (2,813 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-157,81323,437 total
    Common Stock (7,813 underlying)
Footnotes (5)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  • [F3]The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8349, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  • [F5]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Documents

1 file

Issuer

Seres Therapeutics, Inc.

CIK 0001609809

Entity typeother

Related Parties

1
  • filerCIK 0001767321

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:10 PM ET
Size
13.0 KB